Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region

Journal of Infection

Volumn 63, Issue 2, 2011, Pages 114-123

  Hsueh, Po Ren ^a   Hoban, Daryl J ^b   Carmeli, Yehuda ^c   Chen, Shey Ying ^a   Desikan, Sunita ^d   Alejandria, Marissa ^e   Ko, Wen Chien ^f   Binh, Tran Quang ^g  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Chief of Medical Services   (India)

^e UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g CHO RAY HOSPITAL   (Viet Nam)

Author keywords

Antimicrobial resistance; Asia Pacific region; Complicated urinary tract infections; Consensus review; Epidemiology; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FLUCONAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; UNINDEXED DRUG;

ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANDIDIASIS; CATHETER INFECTION; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; CYSTITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ENTEROCOCCAL INFECTION; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE INFECTION; HONG KONG; HOSPITAL INFECTION; HUMAN; INDIA; KIDNEY ABSCESS; KLEBSIELLA PNEUMONIAE; NONHUMAN; PERIRENAL ABSCESS; PHILIPPINES; PRACTICE GUIDELINE; PYELONEPHRITIS; SINGAPORE; TAIWAN; TREATMENT PLANNING; URINARY TRACT INFECTION; VIET NAM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACIFIC ISLANDS; URINARY TRACT INFECTIONS;

EID: 79960891449     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.05.015     Document Type: Article

References (47)

1. Grabe M., Bishop M.C., Bjerklund-Johansen T.E., Botto H., Çek M., Lobel B., et al. Guidelines for urological infections. Eur Assoc Urol 2009.
2. Bader M.S., Hawboldt J., Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010, 122:7-15.
3. Talan D.A., Krishnadasan A., Abrahamian F.M., Stamm W.E., Moran G.J. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- andfluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008, 47:1150-1158. EMERGEncy ID NET Study Group.
4. Khawcharoenporn T., Vasoo S., Ward E., Singh K. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2010 Nov 12, [Epub ahead of print].
5. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999, 29:745-758.
6. Tenke P., Kovacs B., Bjerklund Johansen T.E., Matsumoto T., Tambyah P.A., Naber K.G. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents 2008, 31(Suppl. 1):S68-S78.
7. Hooton T.M., Bradley S.F., Cardenas D.D., Colgan R., Geerlings S.E., Rice J.C., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the infectious diseases society of America. Clin Infect Dis 2010, 50:625-663.
8. Badal R, Bouchillon S, Hawser S, Hackel M, Hsueh PR. Antimicrobial susceptibility of urinary tract Infection pathogens in Asia- SMART 2009. In. 12th Western Pacific Congress of Chemotherapy and Infectious Diseases, December 2-5, 2010, Singapore. Abstract no. P026.
9. Lau S.M., Peng M.Y., Chang F.Y. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect 2004, 37:185-191.
10. Tseng M.H., Lo W.T., Lin W.J., Teng C.S., Chu M.L., Wang C.C. Changing trend in antimicrobial resistance of pediatric uropathogens in Taiwan. Pediat Int 2008, 50:797-800.
11. Chiu N.C., Huang F.Y., Tsai T.S. Urinary tract infections in children. Acta Paedtr Sin 1989, 30:225-231.
12. Wu C.Y., Chiu P.C., Hsieh K.S., Chiu C.L., Shih C.H., Chiou Y.H. Childhood urinary tract infection: a clinical analysis of 597 cases. Acta Paediatr Taiwan 2004, 45:328-333.
13. Kuo L.C., Yu C.J., Kuo M.L., Chen W.N., Chang C.K., Lin H.I., et al. Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study. Int J Antimicrob Agents 2008, 31:420-426.
14. Ko M.C., Liu C.K., Woung L.C., Lee W.K., Jeng H.S., Lu S.H., et al. Species and antimicrobial resistance of uropathogens isolated from patients with urinary catheter. Tohoku J Exp Med 2008, 214:311-319.
15. Mahesh E., Ramesh D., Indumathi V.A., Punith K., Raj Kirthi, Anupama H.A. Complicated urinary tract infection in a tertiary care center in South India. Al Ameen J Med Sci 2010, 2:120-127.
16. Kothari A., Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries 2008, 2:354-358.
17. Dytan A.T., Chua J.A. Surveillance of pathogens and resistance patterns in urinary tract infections. Phil J Microbiol Infect Dis 1999, 28:11-14.
18. Task Force on UTI 2003-04, Philippine practice guidelines Group in infectious diseases. Urinary tract infections in adults: clinical practice guidelines update 2004 2004, vol 2, No 1. Copyright PSMID, PPGG-ID Philippine Society for Microbiology and Infectious Diseases, Quezon City, Philippines, pp. 52-70.
19. Bomasang E.S., Ferrera K.P. Clinical profile and susceptibility pattern of urinary tract infection in post kidney transplant patients at Cardinal Santos Medical Center. Phil J Microbiol Infect Dis 2006, 35:29-37.
20. Mendoza M.T., Liquete R.R., Ona E.T., Alano F.A. Infections in renal allograft recipients. A review of the Philippine experience. Int J Infect Dis 1997, 1:222-225.
21. Alavaren H.F., Lim J.A., Velmonte M.A., Mendoza M.T. Urinary tract infection in patients with indwelling catheter. Phil J Microbiol Infect Dis 1993, 22:65-74.
22. Billote-Domingo K., Mendoza M.T., Tan-Torres T. Catheter-related urinary tract infections: incidence, risk factors and microbiologic profile. Phil J Microbiol Infect Dis 1999, 28:133-138.
23. Evaluation of antibiotic resistance of gram-negative pathogens causing hospital-acquired infections. Tap Chi Y Hoc Thanh Pho Ho Chi Minh 2009, 13-1:286-294. Lêth Anh Thu.
24. Jones R.N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001, 119:S397-S404.
25. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program. Antimicrob Agents Chemother 2007, 2009(53):3280-3284.
26. Karlowsky J.A., Hoban D.J., Decorby M.R., Laing N.M., Zhanel G.G. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American urinary tract infection collaborative alliance-quinolone resistance study. Antimicrob Agents Chemother 2006, 50:2251-2254.
27. Patterson D.L. Collateral damage from antibiotic therapy. Clin Infect Dis 2004, 38(Suppl. 4):S341-S345.
28. Adapted from Johns Hopkins guide to antibiotics http://hopkins-abxguide.org.
29. Poirel L., Leviandier C., Nordmann P. Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital. Antimicrob Agents Chemother 2006, 50:3992-3997.
30. Tumbarello M., Spanu T., Sanguinetti M., Citton R., Montuori E., Leone F., et al. Bloodstream infections caused by extended-spectrum-ß-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006, 50:498-504.
31. Edmiston C.E., Krepel C.J., Kehl K.S., Seabrook G.R., Somberg L.B., Almassi G.H., et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 2005, 56:872-878.
32. Guidelines for antimicrobial therapy of urinary tract infections in Taiwan. J Microbiol Immunol Infect 2000, 33:271-272. The Infectious Diseases Society of the Republic of China, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, Lee CY's Research Foundation for Pediatric Infectious Diseases and Vaccine.
33. Jan I.S., Cheng S.H., Hsu H.C., Hsueh P.R. Physicians' adherence to guidelines for empirical treatment of urinary tract infection in Taiwan. J Microbiol Immunol Infect 2007, 40:532-536.
34. Deguchi T., Nakane K., Yasuda M., Shimizu T., Monden K., Arakawa S., et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents 2010, 35:573-577.
35. Naber K.G., Llorens L., Kaniga K., Kotey P., Hedrich D., Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009, 53:3782-3792.
36. Peterson J., Kaul S., Khashab M., Fisher A.C., Kahn J.B. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008, 71:17-22.
37. Wells W.G., Woods G.L., Jiang Q., Gesser R.M. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004, 53(Suppl. 2):67-74.
38. Tomera K.M., Burdmann E.A., Reyna O.G., Jiang Q., Wimmer W.M., Woods G.L., et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002, 46:2895-2900.
39. Brink A.J., Bizos D., Boffard K.D., Feldman C., Grolman D.C., Pretorius J., et al. Guideline: appropriate use of tigecycline. S Afr Med J 2010, 100:388-394.
40. Krueger W.A., Kempf V.A., Peiffer M., Nagele U., Unertl K.E., Schroeder T.H. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2008, 46:817-820.
41. Geerlings S.E., van Donselaar-van der Pant K.A., Keur I. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2010, 65:2048-2049.
42. Wang J.L., Hsueh P.R. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009, 10:785-796.
43. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute pyelonephritis in women: a 2010 update by the infectious diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis 2011, 52:e103-e120.
44. Guidelines for the use of antifungal agents in patients with invasive fungal infections in Taiwan-revised 2009. J Microbiol Immunol Infect 2010, 43:258-263. The Infectious Diseases Society of Taiwan; The Hematology Society of Taiwan; Taiwan Society of Pulmonary and Critical Care Medicine; Medical Foundation in Memory of Dr Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines.
45. Zorc J.J., Kiddoo D.A., Shaw K.N. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005, 18:417-422.
46. Arguedas A., Cespedes J., Botet F.A., Blumer J., Yogev R., Gesser R., et al. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Int J Antimicrob Agents 2009, 33:163-167.
47. Abdel-Rahman S.M., Kearns G.L., Topelberg S., Jacobs R.F., Mistry G.C., Majumdar A., et al. Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Pediatr Infect Dis J 2010, 29:1072-1076.